You are here:

vildagliptin (Galvus)

Advice

following a full submission:

vildagliptin (Galvus®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of type 2 diabetes mellitus in adults as triple oral therapy in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

SMC restriction: as an alternative dipeptidyl peptidase-4 inhibitor option.

Treatment with vildagliptin reduces HbA1c levels significantly more than placebo when used in combination with metformin and a sulphonylurea. A Bayesian network meta-analysis suggested similar efficacy to another dipeptidyl peptidase-4 inhibitor.
 

Drug Details

Drug Name: vildagliptin (Galvus)
SMC Drug ID: 875/13
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Treatment of type 2 diabetes mellitus in adults as triple oral therapy in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Full submission
Status: Restricted
Date Advice Published: 9 December 2013

Archived Advice

Non submission 13 May 2013

Back